Premium
Intranasal administration of adjuvant‐combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus
Author(s) -
Ichinohe Takeshi,
Ainai Akira,
Ami Yasushi,
Nagata Noriyo,
Iwata Naoko,
Kawaguchi Akira,
Suzaki Yuriko,
Odagiri Takato,
Tashiro Masato,
Takahashi Hidehiro,
Strayer David R.,
Carter William A.,
Chiba Joe,
Tamura Shinichi,
Sata Tetsutaro,
Kurata Takeshi,
Hasegawa Hideki
Publication year - 2010
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.21824
Subject(s) - virology , adjuvant , nasal administration , immunization , influenza a virus subtype h5n1 , virus , antibody , heterologous , vaccination , biology , influenza a virus , influenza vaccine , live attenuated influenza vaccine , medicine , immunology , biochemistry , gene
The effectiveness in cynomolgus macaques of intranasal administration of an influenza A H5N1 pre‐pandemic vaccine combined with synthetic double‐stranded RNA (polyI/polyC12U) as an adjuvant was examined. The monkeys were immunized with the adjuvant‐combined vaccine on weeks 0, 3, and 5, and challenged with the homologous virus 2 weeks after the third immunization. After the second immunization, the immunization induced vaccine‐specific salivary IgA and serum IgG antibodies, as detected by ELISA. The serum IgG antibodies present 2 weeks after the third immunization not only had high neutralizing activity against the homologous virus, they also neutralized significantly heterologous influenza A H5N1 viruses. The vaccinated animals were protected completely from the challenge infection with the homologous virus. These results suggest that intranasal immunization with the Double stranded RNA‐combined influenza A H5N1 vaccine induce mucosal IgA and serum IgG antibodies which could protect humans from homologous influenza A H5N1 viruses which have a pandemic potential. J. Med. Virol. 82:1754–1761, 2010. © 2010 Wiley‐Liss, Inc.